Комбинированное Лечение Метастаза Почечно-Клеточного Рака В Плечевой Кости С Реконструктивно-Пластическим Хирургическим Этапом

Иванов, С. А.; Клименко, А. А.; Курильчик, А. А.; Starodubtsev, A I; Каприн, А. Д.

doi:10.17709/2409-2231-2014-1-80-83

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Остеосинтез связан с меньшим количеством осложнений, простотой и дешевизной вмешательства, но связан с повышенным риском асептической нестабильности на фоне продолженного роста опухоли, если пациенты имеют более длительный срок вы-живаемости. И наоборот, эндопротезирование -более сложный и дорогой метод лечения, однако он предпочтительнее, если ожидается продолжительность жизни более 6 мес [6,7]. Существуют 2 хирургических подхода для лечения метастазов в позвоночник.…”

Section: Introductionunclassified

Development of a prognostic model in patients with metastatic bone lesions to choose surgical treatment: retrospective study

Bukharov¹,

Kurilchik²,

Barashev³

et al. 2023

J. Mod. Onco.

View full text Add to dashboard Cite

Choosing surgical management for patients with metastatic bone lesions is one of the essential problems of modern oncology. Surgical interventions are aimed at palliative treatment in most patients with metastatic skeletal lesions. However, curative resections with reconstruction and plasty steps may be considered in selected cases of a solitary metastatic lesion. The life expectancy prognosis based on the histological structure of the tumor is a significant and decisive factor in choosing the appropriate surgery. Aim. To develop a prognostic model for choosing surgical treatment for metastatic bone lesions. Materials and methods. Treatment analysis of 715 patients with a history of surgery for metastatic bone lesions of various localizations is presented. A total of 780 surgical interventions were performed. Surgeries for the complications of bone metastases were mainly performed on the spine (48.5% of all surgeries), followed by long bones with 247 (35%) surgeries, pelvic bones with 81 (11%) interventions, and the chest wall with 40 (5.5%) surgeries. Results. The most unfavorable prognostic factors in patients with metastatic bone lesions are the histological type of the primary tumor of the rapid growth group (risk ratio [RR]=5.11), visceral metastases (RR=3.1), Charlson Comorbidity Index over 10 (RR=3.07) and presence of critical laboratory abnormalities (RR=2.91), as they have the highest rates of impact on survival (over 2.9). Conclusion. The developed 14-point mathematical score of life expectancy prognosis, which includes five oncological and four clinical factors, defines with an accuracy of 91% the risk groups of good (estimated life expectancy over one year), moderate (6 to 12 months), and poor (less than six months) prognosis in patients with metastatic bone lesions.

show abstract

Section: Introductionunclassified